Value of Endolymphatic Hydrops and Perilymph Signal Intensity in Suspected Ménière Disease

References

1. 1.↵
   1. Lopez-Escamez JA,
   2. Carey J,
   3. Chung WH, et al

   ; Korean Balance Society. Diagnostic criteria for Menière’s disease. J Vestib Res Equilib Res 2015;25:1–7 doi:10.3233/VES-150549 pmid:25882471

   CrossRefPubMed
2. 2.↵
   1. Nakashima T,
   2. Pyykkö I,
   3. Arroll MA, et al

   . Meniere’s disease. Nat Rev Dis Primer 2016;2:16028 doi:10.1038/nrdp.2016.28 pmid:27170253

   CrossRefPubMed
3. 3.↵
   1. Pyykkö I,
   2. Manchaiah V,
   3. Färkkilä M, et al

   . Association between Ménière’s disease and vestibular migraine. Auris Nasus Larynx 2019;46:724–33 doi:10.1016/j.anl.2019.02.002 pmid:31054848

   CrossRefPubMed
4. 4.↵
   1. Neff BA,
   2. Staab JP,
   3. Eggers SD, et al

   . Auditory and vestibular symptoms and chronic subjective dizziness in patients with Ménière’s disease, vestibular migraine, and Ménière’s disease with concomitant vestibular migraine. Otol Neurotol 2012;33:1235–44 doi:10.1097/MAO.0b013e31825d644a pmid:22801040

   CrossRefPubMed
5. 5.↵
   1. Cairns H,
   2. Hallpike F

   . Observations on the pathology of Meniere’s syndrome. Proc R Soc Med 1938;31:1317–36 pmid:19991672

   PubMed
6. 6.↵
   1. Barath K

   . Detection and grading of endolymphatic hydrops in Meniere disease using MR imaging. AJNR Am J Neuroradiol 2014;35:1387–92 doi:10.3174/ajnr.A3856 pmid:24524921

   Abstract/FREE Full Text
7. 7.↵
   1. Naganawa S,
   2. Nakashima T

   . Visualization of endolymphatic hydrops with MR imaging in patients with Ménière’s disease and related pathologies: current status of its methods and clinical significance. Jpn J Radiol 2014;32:191–204 doi:10.1007/s11604-014-0290-4 pmid:24500139

   CrossRefPubMed
8. 8.↵
   1. Ito T,
   2. Kitahara T,
   3. Inui H, et al

   . Endolymphatic space size in patients with Meniere’s disease and healthy controls. Acta Otolaryngol 2016;136:879–82 doi:10.3109/00016489.2016.1169556 pmid:27080254

   CrossRefPubMed
9. 9.↵
   1. Pyykkö I,
   2. Nakashima T,
   3. Yoshida T, et al

   . Ménière’s disease: a reappraisal supported by a variable latency of symptoms and the MRI visualisation of endolymphatic hydrops. BMJ Open 2013;3:e001555–10 doi:10.1136/bmjopen-2012-001555 pmid:23418296

   Abstract/FREE Full Text
10. 10.↵
    1. Nakada T,
    2. Yoshida T,
    3. Suga K, et al

    . Endolymphatic space size in patients with vestibular migraine and Ménière’s disease. J Neurol 2014;261:2079–84 doi:10.1007/s00415-014-7458-9 pmid:25099513

    CrossRefPubMed
11. 11.↵
    1. Gürkov R,
    2. Hornibrook J

    . On the classification of hydropic ear disease (Menière’s disease). HNO 2018;66:455–63 doi:10.1007/s00106-018-0488-3 pmid:29500497

    CrossRefPubMed
12. 12.↵
    1. Attyé A,
    2. Eliezer M,
    3. Boudiaf N, et al

    . MRI of endolymphatic hydrops in patients with Meniere’s disease: a case-controlled study with a simplified classification based on saccular morphology. Eur Radiol 2017;27:3138–46 doi:10.1007/s00330-016-4701-z pmid:27999985

    CrossRefPubMed
13. 13.↵
    1. Shi S,
    2. Zhou F,
    3. Wang W

    . 3D-real IR MRI of Meniere’s disease with partial endolymphatic hydrops. Am J Otolaryngol 2019;40:589–93 doi:10.1016/j.amjoto.2019.05.015 pmid:31113683

    CrossRefPubMed
14. 14.↵
    1. Bernaerts A,
    2. Vanspauwen R,
    3. Blaivie C, et al

    . The value of four stage vestibular hydrops grading and asymmetric perilymphatic enhancement in the diagnosis of Menière’s disease on MRI. Neuroradiology 2019;61:421–29 doi:10.1007/s00234-019-02155-7 pmid:30719545

    CrossRefPubMed
15. 15.↵
    1. Shi S,
    2. Guo P,
    3. Wang W

    . Magnetic resonance imaging of Ménière’s disease after intravenous administration of gadolinium. Ann Otol Rhinol Laryngol 2018;127:777–82 doi:10.1177/0003489418794699 pmid:30156867

    CrossRefPubMed
16. 16.↵
    1. Tagaya M,
    2. Yamazaki M,
    3. Teranishi M, et al

    . Endolymphatic hydrops and blood-labyrinth barrier in Ménière’s disease. Acta Otolaryngol 2011;131:474–79 doi:10.3109/00016489.2010.534114 pmid:21198346

    CrossRefPubMed
17. 17.↵
    1. Yamazaki M,
    2. Naganawa S,
    3. Tagaya M, et al

    . Comparison of contrast effect on the cochlear perilymph after intratympanic and intravenous gadolinium injection. AJNR Am J Neuroradiol 2012;33:773–78 doi:10.3174/ajnr.A2821 pmid:22173762

    Abstract/FREE Full Text
18. 18.↵
    1. Li X,
    2. Wu Q,
    3. Sha Y, et al

    . Gadolinium-enhanced MRI reveals dynamic development of endolymphatic hydrops in Ménière’s disease. Braz J Otorhinolaryngol 2018 Dec 20. [Epub ahead of print] doi:10.1016/j.bjorl.2018.10.014 pmid:30600169

    CrossRefPubMed
19. 19.↵
    1. Yoshida T,
    2. Sugimoto S,
    3. Teranishi M, et al

    . Imaging of the endolymphatic space in patients with Ménière’s disease. Auris Nasus Larynx 2018;45:33–38 doi:10.1016/j.anl.2017.02.002 pmid:28256285

    CrossRefPubMed
20. 20.↵
    1. Attyé A,
    2. Eliezer M,
    3. Medici M, et al

    . In vivo imaging of saccular hydrops in humans reflects sensorineural hearing loss rather than Meniere’s disease symptoms. Eur Radiol 2018;28:2916–22 doi:10.1007/s00330-017-5260-7 pmid:29564597

    CrossRefPubMed
21. 21.↵
    1. Sepahdari AR,
    2. Ishiyama G,
    3. Vorasubin N, et al

    . Delayed intravenous contrast-enhanced 3D FLAIR MRI in Meniere’s disease: correlation of quantitative measures of endolymphatic hydrops with hearing. Clin Imaging 2015;39:26–31 doi:10.1016/j.clinimag.2014.09.014 pmid:25457542

    CrossRefPubMed
22. 22.↵
    1. Kim TY,
    2. Park DW,
    3. Lee YJ, et al

    . Comparison of inner ear contrast enhancement among patients with unilateral inner ear symptoms in MR images obtained 10 minutes and 4 hours after gadolinium injection. AJNR Am J Neuroradiol 2015;36:2367–72 doi:10.3174/ajnr.A4439 pmid:26316569

    Abstract/FREE Full Text
23. 23.↵
    1. Pakdaman MN,
    2. Ishiyama G,
    3. Ishiyama A, et al

    . Blood-labyrinth barrier permeability in Menière disease and idiopathic sudden sensorineural hearing loss: findings on delayed postcontrast 3D-FLAIR MRI. AJNR Am J Neuroradiol 2016;37:1903–08 doi:10.3174/ajnr.A4822 pmid:27256854

    Abstract/FREE Full Text
24. 24.↵
    1. Horii A,
    2. Osaki Y,
    3. Kitahara T, et al

    . Endolymphatic hydrops in Meniere’s disease detected by MRI after intratympanic administration of gadolinium: comparison with sudden deafness. Acta Otolaryngol 2011;131:602–09 doi:10.3109/00016489.2010.548403 pmid:21344957

    CrossRefPubMed
25. 25.↵
    1. Tagaya M,
    2. Teranishi M,
    3. Naganawa S, et al

    . 3 Tesla magnetic resonance imaging obtained 4 hours after intravenous gadolinium injection in patients with sudden deafness. Acta Otolaryngol 2010;130:665–69 doi:10.3109/00016480903384176 pmid:19958242

    CrossRefPubMed
26. 26.↵
    1. Attyé A,
    2. Eliezer M,
    3. Galloux A, et al

    . Endolymphatic hydrops imaging: differential diagnosis in patients with Meniere disease symptoms. Diagn Interv Imaging 2017;98:699–706 doi:10.1016/j.diii.2017.06.002 pmid:28645678

    CrossRefPubMed
27. 27.↵
    1. Phillips J,
    2. Longridge N,
    3. Mallinson A, et al

    . Migraine and vertigo: a marriage of convenience? Headache 2010;50:1362–65 doi:10.1111/j.1526-4610.2010.01745.x pmid:20738416

    CrossRefPubMed
28. 28.↵
    1. Tabet P,
    2. Saliba I

    . Meniere’s disease and vestibular migraine: updates and review of the literature. J Clin Med Res 2017;9:733–44 doi:10.14740/jocmr3126w pmid:28811849

    CrossRefPubMed
29. 29.↵
    1. Rauch SD

    . Clinical hints and precipitating factors in patients suffering from Meniere’s disease. Otolaryngol Clin North Am 2010;43:1011–17 doi:10.1016/j.otc.2010.05.003 pmid:20713240

    CrossRefPubMed
30. 30.↵
    1. Gluth MB

    . On the relationship between Menière’s disease and endolymphatic hydrops. Otol Neurotol 2020;41:242–49 doi:10.1097/MAO.0000000000002502 pmid:31746815

    CrossRefPubMed
31. 31.↵
    1. Da Costa SS,
    2. De Sousa LCA,
    3. De Toledo Piza MR

    . Meniere’s disease: overview, epidemiology, and natural history. Otolaryngol Clin North Am 2002;35:455–95 doi:10.1016/S0030-6665(02)00028-2 pmid:12486835

    CrossRefPubMedWeb of Science